Our patents

International Patent:

Title: Dual Antagonist of PGD2/DPr2 and thromboxane A2/TPr receptor and use for the treatment of maladaptive immune response or thrombotic diathesis

International Application No. PCT/IB2021/052693

Filed March 31, 2021

Our PCT comprising claims for use of ramatroban in COVID-19, long COVID, sickle cell disease, Alzheimer's disease, and silicosis.

US Provisional Patents: 

Title: Use Of a Dual Receptor Antagonist of Prostaglandin D2/DP2 Receptors and Thromboxane A2/TP Receptors for Prophylaxis and/or Treatment of Tissue Fibrosis in Mammals

US PTO Application #63/092,921

Filed October 16, 2020

Title: Use of ramatroban or other blockers of pgd2/dp2 and/or thromboxane a2 receptor for treatment of diseases and conditions related to infection, vascular injury, inflammation, vasculitis, platelet activation, coagulopathy, and thrombosis 

US PTO Application #63/027,751

Filed May 20, 2020

Title: Use Of A CRTH2 Antagonist Such As Ramatroban As A Therapeutic Agent For Treatment Of Adults With Viral Infection Including Covid-19

US PTO Application #63/005,205 

Filed April 3, 2020

Title: Use of Ramatroban as a therapeutic agent for prevention and treatment of viral infections including COVID-19

US PTO Application #63/003,286 

Filed March 31, 2020